1. Berge, E, Whiteley, W, Audebert, H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 2021; 6: I–LXII. DOI: 10.1177/2396987321989865.
Google Scholar | SAGE Journals | ISI2. Purrucker, JC, Haas, K, Rizos, T, et al. Coagulation testing in acute ischemic stroke patients taking Non-Vitamin K antagonist oral anticoagulants. Stroke 2017; 48: 152–158. DOI: 10.1161/STROKEAHA.116.014963.
Google Scholar | Crossref | Medline3. Seiffge, DJ, Traenka, C, Polymeris, A, et al. Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke. J Thromb Thrombolysis 2017; 43: 112–116. DOI: 10.1007/s11239-016-1431-7.
Google Scholar | Crossref | Medline4. Marsch, A, Macha, K, Siedler, G, et al. Direct Oral anticoagulant plasma levels for the management of acute ischemic stroke. Cerebrovasc Dis 2019; 48: 17–25. DOI: 10.1159/000502335.
Google Scholar | Crossref | Medline5. Connors, JM . Testing and monitoring direct oral anticoagulants. Blood 2018; 132: 2009–2015. DOI: 10.1182/blood-2018-04-791541.
Google Scholar | Crossref | Medline6. Maier, CL, Asbury, WH, Duncan, A, et al. Using an old test for new tricks: measuring direct oral anti-Xa drug levels by conventional heparin-calibrated anti-Xa assay. Am J Hematol 2019; 94: E132–E134. DOI: 10.1002/ajh.25434.
Google Scholar | Crossref | Medline7. Touze, E, Gruel, Y, Gouin-Thibault, I, et al. Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants. Eur J Neurol 2018; 25: 747–e752. DOI: 10.1111/ene.13582.
Google Scholar | Crossref | Medline8. Godier, A, Dincq, AS, Martin, AC, et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017; 38: 2431–2439. DOI: 10.1093/eurheartj/ehx403.
Google Scholar | Crossref | Medline9. Hartig, F, Poli, S, Ebner, M, et al. Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds. J Thromb Thrombolysis 2020; 49: 457–467. DOI: 10.1007/s11239-019-01981-z.
Google Scholar | Crossref | Medline10. Pollack, CV,, Reilly, PA, van Ryn, J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. NEJM 2017; 377: 431–441. DOI: 10.1056/NEJMoa1707278.
Google Scholar | Crossref | Medline | ISI11. Connolly, SJ, Crowther, M, Eikelboom, JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. NEJM 2019; 380: 1326–1335. DOI: 10.1056/NEJMoa1814051.
Google Scholar | Crossref | Medline12. Chuck, C, Kim, D, Kalagara, R, et al. Modeling the clinical implications of andexanet alfa in factor Xa inhibitor-associated intracerebral hemorrhage. Neurology 2021. DOI: 10.1212/WNL.0000000000012856.
Google Scholar | Crossref | Medline13. Collins, R., Bowman, L., Landray, M., Peto, R. The magic of randomization versus the myth of real-world evidence. NEJM 2020; 382: 674–678. DOI: 10.1056/NEJMsb1901642.
Google Scholar | Crossref | Medline